BioSpace News Archive

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients

RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy * for all stages of cancer, announced the successful completion of a $40 million extension to its Series D financing, which combined with $110 million raised in 2020, brings the total Series D financing to $150 million.

Alafair Biosciences, Inc., a commercial-stage medical device company and developer of VersaWrap ® , announced today that John Joyoprayitno has been appointed as its new Chief Executive Officer.

Bioelectronica Corporation announced the addition of new members to their team in Reno, NV, as the company continues to experience growing interest in their drug discovery platform, Hypercell®.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement of 10,800,000 units for total proceeds of CAD $2,700,000.

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

Science 37, the industry leader in decentralized clinical trials, announced a strategic partnership with Medgate, a leading international digital health and telemedicine company and operator of Europe’s largest telemedicine center run by physicians.

PureTech Health plc (NASDAQ: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that David-Alexandre C. Gros, M.D., Eledon’s CEO, will present at the H.C. Wainwright Global Life Sciences Conference, which is being held March 9-10.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference.